Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer
{{output}}
Targeted therapies are nowadays a treatment option in metastatic non-small cell lung cancer, for which oncogenic drivers have been identified. The epidermal growth factor-receptor tyrosine kinase inhibitors gefitinib and erlotinib, are the standard of care for... ...
